Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations
Authors
Keywords
Melanoma, BRAF, NRAS, Mutation, EGF, FGF2, EGFR inhibitor, FGFR inhibitor
Journal
PATHOLOGY & ONCOLOGY RESEARCH
Volume 21, Issue 4, Pages 957-968
Publisher
Springer Nature
Online
2015-03-08
DOI
10.1007/s12253-015-9916-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting
- (2013) Tiewei Cheng et al. PLoS One
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
- (2012) Vipin Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Epidermal Growth Factor Facilitates Melanoma Lymph Node Metastasis by Influencing Tumor Lymphangiogenesis
- (2012) Andreas Bracher et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
- (2012) Gholamreza Safaee Ardekani et al. PLoS One
- Anticancer molecules targeting fibroblast growth factor receptors
- (2012) Guang Liang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo
- (2011) Emelie A. Djerf Severinsson et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
- (2011) K. B. Kim et al. CLINICAL CANCER RESEARCH
- Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy
- (2011) Christine Heinzle et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors
- (2011) Alan H. Bryce et al. INVESTIGATIONAL NEW DRUGS
- EGFR in melanoma: clinical significance and potential therapeutic target
- (2011) Barbara Boone et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition
- (2011) Thomas Metzner et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways
- (2011) Heesue Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
- (2011) Vito Guagnano et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase II study of gefitinib in patients with metastatic melanoma
- (2011) Sapna P. Patel et al. MELANOMA RESEARCH
- Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials
- (2011) Montserrat Blanco Codesido et al. ONCOLOGY
- Receptor tyrosine kinases and their activation in melanoma
- (2011) David J. Easty et al. Pigment Cell & Melanoma Research
- Targeting the RAS pathway in melanoma
- (2011) Zhenyu Ji et al. TRENDS IN MOLECULAR MEDICINE
- Different Patterns of Expression of the erbB Family of Receptor Tyrosine Kinases in Common Nevi, Dysplastic Nevi, and Primary Malignant Melanomas: An Immunohistochemical Study
- (2010) Meora Feinmesser et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?
- (2010) József Tímár et al. CLINICAL & EXPERIMENTAL METASTASIS
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
- (2009) N. Schicher et al. CLINICAL CANCER RESEARCH
- ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
- (2009) Emelie A. Djerf et al. MELANOMA RESEARCH
- Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
- (2009) Michael G. Gartside et al. MOLECULAR CANCER RESEARCH
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Cellular Signaling by Fibroblast Growth Factors (FGFs) and Their Receptors (FGFRs) in Male Reproduction
- (2008) Leanne M. Cotton et al. ENDOCRINE REVIEWS
- Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism
- (2008) Georgia Chalkiadaki et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Phospho-ERK Staining Is a Poor Indicator of the Mutational Status of BRAF and NRAS in Human Melanoma
- (2008) Roland Houben et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide
- (2008) Tobias Sinnberg et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started